A novel biomarker to predict DNA-Repair-inhibitor response in stage I-III high risk breast cancer patients

A. Barcaru, M.M. Kuilman, D. Wolf, C. Yau, E.B.M. Choy, W.M. Audeh, L. Brown-Swigart, G.L. Hirst, F.W. Symmans,M.C. Liu,R. Nanda,L.J. Esserman,L.J. van ‘t Veer,A.M. Glas, L. Mittempergher

European Journal of Cancer（2022）

引用 0|浏览0

暂无评分

摘要

Background: The combinations of PARP inhibitor (PARPi) and platinum-based drugs are gaining more interest as first line therapy for early-stage breast cancer. The I-SPY2 trial (NCT01042379) qualified different DNA-Damage-Repair (DDR) deficiency biomarkers that predict response to DNA damage agents. Here we aimed to translate the I-SPY2 research findings to a robust clinical grade platform signature to predict sensitivity to PARPi and platinum-based chemotherapy.

查看译文

关键词

novel biomarker,dna-repair-inhibitor dna-repair-inhibitor,breast cancer,i-iii

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要